CYP2D6‐debrisoquine hydroxylase gene polymorphism in multiple system atrophy
Identifieur interne : 003989 ( Istex/Corpus ); précédent : 003988; suivant : 003990CYP2D6‐debrisoquine hydroxylase gene polymorphism in multiple system atrophy
Auteurs : V. Planté-Bordeneuve ; O. Bandmann ; G. Wenning ; N. P. Quinn ; S. E. Daniel ; HardingSource :
- Movement Disorders [ 0885-3185 ] ; 1995-05.
English descriptors
Abstract
Molecular genetic studies of the cytochrome P450 system enzyme CYP2D6, which hydroxylates debrisoquine, have indicated an excess of mutant alleles in large series of patients with Parkinosn's disease (PD) when compared with controls. We have investigated CYP2D6 polymorphism in 91 patients with multiple system atrophy (MSA) in order to determine if this finding is specific to PD or if there is similar evidence of genetic susceptibility to neurotoxicity in MSA. The distribution of CYP2D6 alleles was not significantly different between MSA patients and controls, and there were fewer poor metabolisers in the MSA group than in the control group.
Url:
DOI: 10.1002/mds.870100307
Links to Exploration step
ISTEX:A74D2BAFCD624AC24D50C184996E977E8D1C8BCALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">CYP2D6‐debrisoquine hydroxylase gene polymorphism in multiple system atrophy</title><author><name sortKey="Plante Ordeneuve, V" sort="Plante Ordeneuve, V" uniqKey="Plante Ordeneuve V" first="V." last="Planté-Bordeneuve">V. Planté-Bordeneuve</name><affiliation><mods:affiliation>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</mods:affiliation></affiliation></author><author><name sortKey="Bandmann, O" sort="Bandmann, O" uniqKey="Bandmann O" first="O." last="Bandmann">O. Bandmann</name><affiliation><mods:affiliation>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</mods:affiliation></affiliation></author><author><name sortKey="Wenning, G" sort="Wenning, G" uniqKey="Wenning G" first="G." last="Wenning">G. Wenning</name><affiliation><mods:affiliation>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</mods:affiliation></affiliation></author><author><name sortKey="Quinn, N P" sort="Quinn, N P" uniqKey="Quinn N" first="N. P." last="Quinn">N. P. Quinn</name><affiliation><mods:affiliation>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</mods:affiliation></affiliation></author><author><name sortKey="Daniel, S E" sort="Daniel, S E" uniqKey="Daniel S" first="S. E." last="Daniel">S. E. Daniel</name><affiliation><mods:affiliation>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</mods:affiliation></affiliation></author><author><name sortKey="Harding" sort="Harding" uniqKey="Harding" last="Harding">Harding</name><affiliation><mods:affiliation>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A74D2BAFCD624AC24D50C184996E977E8D1C8BCA</idno><date when="1995" year="1995">1995</date><idno type="doi">10.1002/mds.870100307</idno><idno type="url">https://api.istex.fr/document/A74D2BAFCD624AC24D50C184996E977E8D1C8BCA/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003989</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">CYP2D6‐debrisoquine hydroxylase gene polymorphism in multiple system atrophy</title><author><name sortKey="Plante Ordeneuve, V" sort="Plante Ordeneuve, V" uniqKey="Plante Ordeneuve V" first="V." last="Planté-Bordeneuve">V. Planté-Bordeneuve</name><affiliation><mods:affiliation>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</mods:affiliation></affiliation></author><author><name sortKey="Bandmann, O" sort="Bandmann, O" uniqKey="Bandmann O" first="O." last="Bandmann">O. Bandmann</name><affiliation><mods:affiliation>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</mods:affiliation></affiliation></author><author><name sortKey="Wenning, G" sort="Wenning, G" uniqKey="Wenning G" first="G." last="Wenning">G. Wenning</name><affiliation><mods:affiliation>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</mods:affiliation></affiliation></author><author><name sortKey="Quinn, N P" sort="Quinn, N P" uniqKey="Quinn N" first="N. P." last="Quinn">N. P. Quinn</name><affiliation><mods:affiliation>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</mods:affiliation></affiliation></author><author><name sortKey="Daniel, S E" sort="Daniel, S E" uniqKey="Daniel S" first="S. E." last="Daniel">S. E. Daniel</name><affiliation><mods:affiliation>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</mods:affiliation></affiliation></author><author><name sortKey="Harding" sort="Harding" uniqKey="Harding" last="Harding">Harding</name><affiliation><mods:affiliation>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1995-05">1995-05</date><biblScope unit="vol">10</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="277">277</biblScope><biblScope unit="page" to="278">278</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">A74D2BAFCD624AC24D50C184996E977E8D1C8BCA</idno><idno type="DOI">10.1002/mds.870100307</idno><idno type="ArticleID">MDS870100307</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cytochrome P450</term><term>Multiple system atrophy</term><term>Parkinson's disease</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Molecular genetic studies of the cytochrome P450 system enzyme CYP2D6, which hydroxylates debrisoquine, have indicated an excess of mutant alleles in large series of patients with Parkinosn's disease (PD) when compared with controls. We have investigated CYP2D6 polymorphism in 91 patients with multiple system atrophy (MSA) in order to determine if this finding is specific to PD or if there is similar evidence of genetic susceptibility to neurotoxicity in MSA. The distribution of CYP2D6 alleles was not significantly different between MSA patients and controls, and there were fewer poor metabolisers in the MSA group than in the control group.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>V. Planté‐Bordeneuve</name><affiliations><json:string>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</json:string></affiliations></json:item><json:item><name>O. Bandmann</name><affiliations><json:string>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</json:string></affiliations></json:item><json:item><name>G. Wenning</name><affiliations><json:string>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</json:string></affiliations></json:item><json:item><name>N. P. Quinn</name><affiliations><json:string>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</json:string></affiliations></json:item><json:item><name>S. E. Daniel</name><affiliations><json:string>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</json:string></affiliations></json:item><json:item><name>Prof. Harding</name><affiliations><json:string>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Multiple system atrophy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Cytochrome P450</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Molecular genetic studies of the cytochrome P450 system enzyme CYP2D6, which hydroxylates debrisoquine, have indicated an excess of mutant alleles in large series of patients with Parkinosn's disease (PD) when compared with controls. We have investigated CYP2D6 polymorphism in 91 patients with multiple system atrophy (MSA) in order to determine if this finding is specific to PD or if there is similar evidence of genetic susceptibility to neurotoxicity in MSA. The distribution of CYP2D6 alleles was not significantly different between MSA patients and controls, and there were fewer poor metabolisers in the MSA group than in the control group.</abstract><qualityIndicators><score>2.308</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>648</abstractCharCount><pdfWordCount>1120</pdfWordCount><pdfCharCount>7035</pdfCharCount><pdfPageCount>2</pdfPageCount><abstractWordCount>99</abstractWordCount></qualityIndicators><title>CYP2D6‐debrisoquine hydroxylase gene polymorphism in multiple system atrophy</title><genre><json:string>Serial article</json:string></genre><host><volume>10</volume><pages><total>2</total><last>278</last><first>277</first></pages><issn><json:string>0885-3185</json:string></issn><issue>3</issue><subject><json:item><value>Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>1995</publicationDate><copyrightDate>1995</copyrightDate><doi><json:string>10.1002/mds.870100307</json:string></doi><id>A74D2BAFCD624AC24D50C184996E977E8D1C8BCA</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/A74D2BAFCD624AC24D50C184996E977E8D1C8BCA/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/A74D2BAFCD624AC24D50C184996E977E8D1C8BCA/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/A74D2BAFCD624AC24D50C184996E977E8D1C8BCA/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">CYP2D6‐debrisoquine hydroxylase gene polymorphism in multiple system atrophy</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>1995</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">CYP2D6‐debrisoquine hydroxylase gene polymorphism in multiple system atrophy</title><author><persName><forename type="first">V.</forename><surname>Planté‐Bordeneuve</surname></persName><affiliation>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</affiliation></author><author><persName><forename type="first">O.</forename><surname>Bandmann</surname></persName><affiliation>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</affiliation></author><author><persName><forename type="first">G.</forename><surname>Wenning</surname></persName><affiliation>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</affiliation></author><author><persName><forename type="first">N. P.</forename><surname>Quinn</surname></persName><affiliation>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</affiliation></author><author><persName><forename type="first">S. E.</forename><surname>Daniel</surname></persName><affiliation>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</affiliation></author><author><persName><surname>Harding</surname><roleName type="degree">Prof.</roleName></persName><note type="correspondence"><p>Correspondence: University Department of Clinical Neurology (Neurogenetics Section), Institute of Neurology, Queen Square, London WC1N 3BG, U.K.</p></note><affiliation>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1995-05"></date><biblScope unit="vol">10</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="277">277</biblScope><biblScope unit="page" to="278">278</biblScope></imprint></monogr><idno type="istex">A74D2BAFCD624AC24D50C184996E977E8D1C8BCA</idno><idno type="DOI">10.1002/mds.870100307</idno><idno type="ArticleID">MDS870100307</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1995</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Molecular genetic studies of the cytochrome P450 system enzyme CYP2D6, which hydroxylates debrisoquine, have indicated an excess of mutant alleles in large series of patients with Parkinosn's disease (PD) when compared with controls. We have investigated CYP2D6 polymorphism in 91 patients with multiple system atrophy (MSA) in order to determine if this finding is specific to PD or if there is similar evidence of genetic susceptibility to neurotoxicity in MSA. The distribution of CYP2D6 alleles was not significantly different between MSA patients and controls, and there were fewer poor metabolisers in the MSA group than in the control group.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Multiple system atrophy</term></item><item><term>Cytochrome P450</term></item><item><term>Parkinson's disease</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1994-09-08">Registration</change><change when="1995-05">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/A74D2BAFCD624AC24D50C184996E977E8D1C8BCA/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="30"><doi origin="wiley" registered="yes">10.1002/mds.v10:3</doi><numberingGroup><numbering type="journalVolume" number="10">10</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="1995-05">May 1995</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="7" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.870100307</doi><idGroup><id type="unit" value="MDS870100307"></id></idGroup><countGroup><count type="pageTotal" number="2"></count></countGroup><titleGroup><title type="articleCategory">Article</title><title type="tocHeading1">Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 1995 Movement Disorder Society</copyright><eventGroup><event type="manuscriptAccepted" date="1994-09-08"></event><event type="firstOnline" date="2004-10-12"></event><event type="publishedOnlineFinalForm" date="2004-10-12"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">277</numbering><numbering type="pageLast">278</numbering></numberingGroup><correspondenceTo>University Department of Clinical Neurology (Neurogenetics Section), Institute of Neurology, Queen Square, London WC1N 3BG, U.K.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS870100307.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="10"></count></countGroup><titleGroup><title type="main" xml:lang="en"><i>CYP2D6</i>‐debrisoquine hydroxylase gene polymorphism in multiple system atrophy</title><title type="short" xml:lang="en">POLYMORPHISM IN MULTIPLE SYSTEM ATROPHY</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>V.</givenNames><familyName>Planté‐Bordeneuve</familyName></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>O.</givenNames><familyName>Bandmann</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>G.</givenNames><familyName>Wenning</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>N. P.</givenNames><familyName>Quinn</familyName></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>S. E.</givenNames><familyName>Daniel</familyName></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><honorifics>Prof.</honorifics><givenNames>A. E.</givenNames><familyName>Harding</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="GB" type="organization"><unparsedAffiliation>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Multiple system atrophy</keyword><keyword xml:id="kwd2">Cytochrome P450</keyword><keyword xml:id="kwd3">Parkinson's disease</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Molecular genetic studies of the cytochrome P450 system enzyme <i>CYP2D6</i>, which hydroxylates debrisoquine, have indicated an excess of mutant alleles in large series of patients with Parkinosn's disease (PD) when compared with controls. We have investigated <i>CYP2D6</i> polymorphism in 91 patients with multiple system atrophy (MSA) in order to determine if this finding is specific to PD or if there is similar evidence of genetic susceptibility to neurotoxicity in MSA. The distribution of <i>CYP2D6</i> alleles was not significantly different between MSA patients and controls, and there were fewer poor metabolisers in the MSA group than in the control group.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>CYP2D6‐debrisoquine hydroxylase gene polymorphism in multiple system atrophy</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>POLYMORPHISM IN MULTIPLE SYSTEM ATROPHY</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>‐debrisoquine hydroxylase gene polymorphism in multiple system atrophy</title></titleInfo><name type="personal"><namePart type="given">V.</namePart><namePart type="family">Planté‐Bordeneuve</namePart><affiliation>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">O.</namePart><namePart type="family">Bandmann</namePart><affiliation>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Wenning</namePart><affiliation>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N. P.</namePart><namePart type="family">Quinn</namePart><affiliation>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S. E.</namePart><namePart type="family">Daniel</namePart><affiliation>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="termsOfAddress">Prof.</namePart><namePart type="family">Harding</namePart><affiliation>University Department of Clinical Neurology (Neurogenetics and Movement Disorders Sections and Parkinson's Disease Society Brain Bank), Institute of Neurology, London, England</affiliation><description>Correspondence: University Department of Clinical Neurology (Neurogenetics Section), Institute of Neurology, Queen Square, London WC1N 3BG, U.K.</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">1995-05</dateIssued><dateValid encoding="w3cdtf">1994-09-08</dateValid><copyrightDate encoding="w3cdtf">1995</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">1</extent><extent unit="references">10</extent></physicalDescription><abstract lang="en">Molecular genetic studies of the cytochrome P450 system enzyme CYP2D6, which hydroxylates debrisoquine, have indicated an excess of mutant alleles in large series of patients with Parkinosn's disease (PD) when compared with controls. We have investigated CYP2D6 polymorphism in 91 patients with multiple system atrophy (MSA) in order to determine if this finding is specific to PD or if there is similar evidence of genetic susceptibility to neurotoxicity in MSA. The distribution of CYP2D6 alleles was not significantly different between MSA patients and controls, and there were fewer poor metabolisers in the MSA group than in the control group.</abstract><subject lang="en"><genre>Keywords</genre><topic>Multiple system atrophy</topic><topic>Cytochrome P450</topic><topic>Parkinson's disease</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>277</start><end>278</end><total>2</total></extent></part></relatedItem><identifier type="istex">A74D2BAFCD624AC24D50C184996E977E8D1C8BCA</identifier><identifier type="DOI">10.1002/mds.870100307</identifier><identifier type="ArticleID">MDS870100307</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1995 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003989 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 003989 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:A74D2BAFCD624AC24D50C184996E977E8D1C8BCA
|texte= CYP2D6‐debrisoquine hydroxylase gene polymorphism in multiple system atrophy
}}
| This area was generated with Dilib version V0.6.23. |  |